TargetBeta
BRD4
bromodomain containing 4 · also HUNKI, MCAP, CAP, HUNK1 · Bromodomain and extra-terminal domain family
3 programs in company-led studies act on BRD4, from 3 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| pelabresibrule | Novartis | inhibitor | phase 3 | 117 running | BRD2, BRD3, BRDT | ChEMBL |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | – | phase 3 | 33 running | AR | a judged reading |
| BRD4 Degrader MT-4561rule | Tanabe Pharma | degrader | phase 2 | 11 running | – | NCIt |
Conditions their studies are in
- Hematologic Neoplasms, 1 program
- Lymphoma, 1 program
- Lymphoma, Follicular, 1 program
- Multiple Myeloma, 1 program
- Primary Myelofibrosis, 1 program
- Prostatic Neoplasms, 1 program
- Squamous Cell Carcinoma of Head and Neck, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 14, 2028Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 · Johnson & Johnson · phase 3 · NCT07906717
- Mar 9, 2028pelabresib · Novartis · phase 3 · NCT07340190
- Aug 2028BRD4 Degrader MT-4561 · Tanabe Pharma · phase 2 · NCT06943521
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.